Allergan plc (NYSE: AGN) issued the following statement regarding ongoing litigation on patents related to NAMENDA XR (memantine hydrochloride) extended ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE